Crossmark

Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis

Crossref DOI link: https://doi.org/10.1038/s41598-020-58994-5

Published Online: 2020-02-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kanbayashi, Yuko

Ishikawa, Takeshi

Tabuchi, Yusuke

Sakaguchi, Koichi

Ouchi, Yoshimi

Otsuji, Eigo

Takayama, Koichi

Taguchi, Tetsuya
License Information

Text and Data Mining valid from 2020-02-06

Version of Record valid from 2020-02-06
More Information

Article History

Received: 7 November 2019

Accepted: 23 January 2020

First Online: 6 February 2020

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below